中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(12): 2656-2660

Mechanism and treatment prospects of macrophage metabolic reprogramming in regulating acute-on-chronic liver failure

DOI: 10.12449/JCH251230

  • Department of Infectious Diseases，Hebei Medical University Third Hospital，Shijiazhuang 050051，China

Research funding:

Central Guiding Local Technology Development Fund Project （Construction of Science and Technology Innovation Base） (236Z7749G);

Hebei Province Graduate Innovation Funding Project (CXZZBS2026110)

More Information
  • Corresponding author: ZHAO Caiyan， zhaocy@hebmu.edu.cn （ORCID： 0000-0001-5997-4641）
  • Received Date: 2025-04-25
  • Accepted Date: 2025-06-10
  • Published Date: 2025-12-25
    Abstract
  • Metabolic reprogramming is a prerequisite and important marker for macrophage phenotypic transition， and different macrophage phenotypes are involved in the pathogenesis of acute-on-chronic liver failure （ACLF） by regulating the balance of inflammatory responses， thereby becoming the potential targets for ACLF treatment. This article focuses on the changes in macrophage metabolic reprogramming during ACLF and its mechanism in mediating ACLF severity and prognosis by regulating energy metabolism and immune inflammation， in order to provide new ideas and directions for developing prevention and control strategies for ACLF based on macrophage metabolic reprogramming.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    TREBICKA J, HERNAEZ R, SHAWCROSS DL, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure(ACLF) and the role of biomarkers[J]. Gut, 2024, 73( 6): 1015- 1024. DOI: 10.1136/gutjnl-2023-330584.
    [2]
    PIANO S, MAHMUD N, CARACENI P, et al. Mechanisms and treatment approaches for ACLF[J]. Liver Int, 2025, 45( 3): e15733. DOI: 10.1111/liv.15733.
    [3]
    GUILLIAMS M, SCOTT CL. Liver macrophages in health and disease[J]. Immunity, 2022, 55( 9): 1515- 1529. DOI: 10.1016/j.immuni.2022.08.002.
    [4]
    ZHANG Y, WU DS, TIAN XL, et al. From hepatitis B virus infection to acute-on-chronic liver failure: The dynamic role of hepatic macrophages[J]. Scand J Immunol, 2024, 99( 3): e13349. DOI: 10.1111/sji.13349.
    [5]
    GAO CC, BAI J, HAN H, et al. The versatility of macrophage heterogeneity in liver fibrosis[J]. Front Immunol, 2022, 13: 968879. DOI: 10.3389/fimmu.2022.968879.
    [6]
    XIAO Y, LU J, XU SY, et al. Metabolic differences among patients with cirrhosis using Q exactive hybrid quadrupole orbitrap mass spectrometry technology[J]. J Proteome Res, 2024, 23( 12): 5352- 5359. DOI: 10.1021/acs.jproteome.4c00437.
    [7]
    ZHANG IW, CURTO A, LÓPEZ-VICARIO C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure[J]. J Hepatol, 2022, 76( 1): 93- 106. DOI: 10.1016/j.jhep.2021.08.009.
    [8]
    KORF H, du PLESSIS J, van PELT J, et al. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity[J]. Gut, 2019, 68( 10): 1872- 1883. DOI: 10.1136/gutjnl-2018-316888.
    [9]
    ZHANG Y, TIAN XL, LI JQ, et al. Mitochondrial dysfunction affects hepatic immune and metabolic remodeling in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2024, 30( 8): 881- 900. DOI: 10.3748/wjg.v30.i8.881.
    [10]
    RAO JH, WANG H, NI M, et al. FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2[J]. Gut, 2022, 71( 12): 2539- 2550. DOI: 10.1136/gutjnl-2021-325150.
    [11]
    MA JW, WEI KK, LIU JW, et al. Glycogen metabolism regulates macrophage-mediated acute inflammatory responses[J]. Nat Commun, 2020, 11: 1769. DOI: 10.1038/s41467-020-15636-8.
    [12]
    CUI YX, CHEN JH, ZHANG Z, et al. The role of AMPK in macrophage metabolism, function and polarisation[J]. J Transl Med, 2023, 21( 1): 892. DOI: 10.1186/s12967-023-04772-6.
    [13]
    HAN ZY, SHEN YH, YAN YQ, et al. Metabolic reprogramming shapes post-translational modification in macrophages[J]. Mol Aspects Med, 2025, 102: 101338. DOI: 10.1016/j.mam.2025.101338.
    [14]
    ZHANG Y, TAN WT, WANG XB, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79( 5): 1159- 1171. DOI: 10.1016/j.jhep.2023.07.011.
    [15]
    LIU PS, WANG HP, LI XY, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming[J]. Nat Immunol, 2017, 18( 9): 985- 994. DOI: 10.1038/ni.3796.
    [16]
    YU ZJ, LI JJ, REN ZG, et al. Switching from fatty acid oxidation to glycolysis improves the outcome of acute-on-chronic liver failure[J]. Adv Sci, 2020, 7( 7): 1902996. DOI: 10.1002/advs.201902996.
    [17]
    BOSMANS LA, van TIEL CM, AARTS SABM, et al. Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages’ transition into a pro-inflammatory state[J]. Cardiovasc Res, 2023, 119( 5): 1146- 1160. DOI: 10.1093/cvr/cvac084.
    [18]
    LIU PS, CHEN YT, LI XY, et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions[J]. Nat Immunol, 2023, 24( 3): 452- 462. DOI: 10.1038/s41590-023-01430-3.
    [19]
    ZHANG QY, SONG QL, LIU S, et al. Integrated transcriptomic and metabolomic analysis reveals the metabolic programming of GM-CSF-and M-CSF-differentiated mouse macrophages[J]. Front Immunol, 2023, 14: 1230772. DOI: 10.3389/fimmu.2023.1230772.
    [20]
    MAO YX, SHI D, LI G, et al. Citrulline depletion by ASS1 is required for proinflammatory macrophage activation and immune responses[J]. Mol Cell, 2022, 82( 3): 527- 541. e 7. DOI: 10.1016/j.molcel.2021.12.006.
    [21]
    YAN JW, HORNG T. Lipid metabolism in regulation of macrophage functions[J]. Trends Cell Biol, 2020, 30( 12): 979- 989. DOI: 10.1016/j.tcb.2020.09.006.
    [22]
    YANG Y, NI M, ZONG RB, et al. Targeting Notch1-YAP circuit reprograms macrophage polarization and alleviates acute liver injury in mice[J]. Cell Mol Gastroenterol Hepatol, 2023, 15( 5): 1085- 1104. DOI: 10.1016/j.jcmgh.2023.01.002.
    [23]
    SÁNCHEZ-RODRÍGUEZ MB, TÉLLEZ É, CASULLERAS M, et al. Reduced plasma extracellular vesicle CD5L content in patients with acute-on-chronic liver failure: Interplay with specialized pro-resolving lipid mediators[J]. Front Immunol, 2022, 13: 842996. DOI: 10.3389/fimmu.2022.842996.
    [24]
    PENG B, LI H, LIU K, et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure[J]. J Transl Med, 2023, 21( 1): 419. DOI: 10.1186/s12967-023-04294-1.
    [25]
    MAHESHWARI D, KUMAR D, JAGDISH RK, et al. Bioenergetic failure drives functional exhaustion of monocytes in acute-on-chronic liver failure[J]. Front Immunol, 2022, 13: 856587. DOI: 10.3389/fimmu.2022.856587.
    [26]
    MAIWALL R, BAJPAI M, CHOUDHURY AK, et al. Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: A propensity-score matched study from AARC[J]. Liver Int, 2021, 41( 5): 1083- 1096. DOI: 10.1111/liv.14806.
    [27]
    LI ZH, WANG JY, LI XL, et al. Mesenchymal stem cell-regulated miRNA-mRNA landscape in acute-on-chronic liver failure[J]. Genomics, 2023, 115( 6): 110737. DOI: 10.1016/j.ygeno.2023.110737.
    [28]
    GAO YH, MI NN, WU WX, et al. Transfer of inflammatory mitochondria via extracellular vesicles from M1 macrophages induces ferroptosis of pancreatic beta cells in acute pancreatitis[J]. J Extracell Vesicles, 2024, 13( 2): e12410. DOI: 10.1002/jev2.12410.
    [29]
    XUE JH, CHEN F, WANG J, et al. Emodin protects against concanavalin A-induced hepatitis in mice through inhibiting activation of the p38 MAPK-NF-κB signaling pathway[J]. Cell Physiol Biochem, 2015, 35( 4): 1557- 1570. DOI: 10.1159/000373971.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (43) PDF downloads(15) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return